Brought to you by 
Mundipharma to develop Novelos's lung cancer compound NOV002
23 Jul 2019
Executive Summary
Drug discovery company Novelos Therapeutics has licensed Mundipharma (an affiliate of Purdue Pharma) exclusive European and Asian rights to its lead project NOV002, in Phase III for stage IIIb/IV non-small cell lung cancer and in Phase II for ovarian and breast cancers. The deal excludes China, Hong Kong, Taiwan, and Macau, where the candidate is already partnered with Lee's Pharmaceutical.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mundipharma to develop Novelos's lung cancer compound NOV002
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice